Shots:

• The P-III KATHERINE study involves assessing of Kadcyla vs Herceptin + taxane-based CT as an adjuvant treatment in people with HER2-positive early breast cancer (eBC) who didn’t achieve pathological complete response to neoadjuvant treatment
• The P-III KATHERINE study met 1EP endpoints i.e. iDFS the time period to invasive breast cancer recurrence or death. No new safety signals were observed & included DFS & OS as 2EP
• Kadcyla is an Ab-drug conjugate (ADC) for inducing CT into HER2-positive cancer cells- approved drug in 104 countries including the US and EU. Roche is licensing a technology for Kadcyla from ImmunoGen

Ref: Roche | Image: Fierce Biotech